About Us
World-recognized R&D company for creating market value through innovative new drugs

Our history

2020
07

EU phase 2 clinical trial application for endometrial treatment (NCE403_TU2670)

New NASH and IPF treatments selected for National grant for innovative growth of small/medium-sized venture companies in BIG 3 areas (Ministry of SMEs and Startups)

02
Clinical sample production agreement with Thermo-Fisher Scientific for Hemophilia bypassing therapy (TU7710)
2019
11
KOSDAQ IPO (Public offering of 30billion won)
05
Series C funding (40billion won)
02
Technology transfer of endometriosis treatment to Daewon Pharmaceutical Co., Ltd. (NCE403_TU2670)
2018
12

New drug candidate for lung disease
(NCE401_TU2218)

Technology transfer to Chiesi, a global
pharmaceutical company

09
Selected for a government grant to develop new hemophilia treatments (Ministry of SMEs and Startups)
07

Endometriosis treatment (NCE403_TU2670)

EU phase 1b clinical trial CTA approval (Germany) Series B funding

Selection for government grant for the development of a new immunization anticancer treatment (Ministry of Health and Welfare)

05
Series B funding (23.5billion won )
04
Selected as a National grant for the development of new cancer immunotherapeutic drugs. (Ministry of Health and Welfare)
2017
05
Series A funding (12billion won )
2016
12
Tiumbio Co. Established